MaxCyte is committed to the success of our partners and the partnership. We collaborate through a flexible model, tailoring our licenses to meet the needs of our partners and their target market.
We provide two avenues for partnerships:
Our novel and proprietary CARMA™ Platform provides a unique approach to autologous CAR therapy with the ability to load human mRNA targets for many different tumor types.
Our CAR drug products are focused on solid tumor targets, designed for a safer profile with less complexity in the manufacturing process
For more information on licensing either our CARMA Platform or cell therapy drug products, email us at email@example.com.
Learn about cutting-edge applications, new resources, and upcoming events.
Subscribe to our e-Newsletter